Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01566773 · ClinicalTrials.gov registry record · Phase 2
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT01566773: Completed Phase 2 study, sponsored by Pearl Therapeutics.
NCT01566773 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01566773, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
Primary Outcome
Forced expiratory volume in 1 second (FEV1) normalized area under the curve 0-12 hours (AUC0-12) following chronic dosing for 14 days.
Interventions
- DRUG Tiotropium Bromide
- DRUG PT001 MDI
- DRUG PT001 Placebo MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01566773 record still lists
NCT01566773 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Tiotropium Bromide is the first listed.
NCT01566773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01566773 about?
NCT01566773 is a clinical study titled "PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD". The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
What is the current status of trial NCT01566773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2012-03. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01566773?
The interventions under investigation include: Tiotropium Bromide (DRUG), PT001 MDI (DRUG), PT001 Placebo MDI (DRUG).
Who is sponsoring clinical trial NCT01566773?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01566773's enrollment target sits among peer trials
140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia